Crigen Accor Life Science

Crigen Accor Life Science is a Malaysian-based private label health and beauty one stop manufacturer. Its mission is to change the world 1 product at a time by delivering high quality, eco-friendly, safe, and affordable health and beauty private label products to its partners and customers.

Campaign Closed RM 1,500,000 raised

300% of target	0 days left
Investors	6
Min Target	RM 500,000
Max Target	RM 1,500,000

Introduction

Our mission in Crigen Accor Life Science is to change the world 1 product at a time by delivering high quality, eco-friendly, safe and affordable health and beauty private label products to our partners and customers. We are a Malaysian-based private label health and beauty products manufacturer and also an original equipment and contract manufacturing company.

We believe that by unlocking the power of nature through scientific precision and innovation, we are able to design highly responsible, economical and consumer-friendly products that are highly effective for our customers.

What We Do

The Challenge

Reliability Issues

Current products in the market do not always deliver on the desired effect
Lack of first-hand knowledge based on consumer feedback
There is lack of innovation in the research & development phase and information is simply recycled.

High MOQ, Production Cost & Initial Startup Cost

Large volumes are usually required to start production
Only big brands with a large budget are usually served
Products are not tested for market fit before launch
High risk when launching new products due to high capital investment

Lack of Support in Product Sales & Marketing

Traditional manufacturers only provide manufacturing services
Outdated designs and marketing approach

Our Solution

Crigen Accor has already formulated and designed 5 products to start with and we are now ready to move into manufacturing and production. We are looking to set up a manufacturing plant in Semenyih, Selangor. We have also gained major traction by securing an exclusive contract from Crigen Resources Sdn Bhd worth approximately RM 1.5 million. With this round of funding, our objective is to ramp up our manufacturing plant and expand our sales and marketing efforts.

Geo Gun with Serum

Oat milk Protein

Hydration mask

Hypochlorous Acid

Hand Sanitizer

There are ongoing applications for GMP Certification for our factories.
We are careful when selecting the ingredients used to develop our products. With our experience in operating various beauty and wellness centers, we have first-hand knowledge on the characteristics for beauty products and market insight.
We partner and work with renowned chemists and scientists locally and globally.

We work with small businesses and incubate them into larger brands
We are able to provide reliable, high-quality products within short time frames. Through our manufacturing techniques, the product prototype and sample is able to be assessed by our customers alongside our development team.
Testing is carried out as often as necessary until the customer's needs are met in order to ensure product reliability and cost savings for our customers.
Our curative designs and formulations cater specifically to beauty salons, and boutique spas.

We provide consultation on product launching with our first-hand experience and market insight in the health and beauty industry
We help our customers design and propose packaging which is suitable to the target market.

Why Are We Different

Our customers are able to conduct tests to determine market suitability of the product before placing large orders
We have over 17 years of first-hand experience in the health and beauty market
We are a one-stop solution from R&D, product development, manufacturing, design and marketing
Boutique Spas, pharmacies and beauty salons can build their own brands with low startup costs and MOQ (Minimum Order Quantity)

Our Revenue Model

Product Design and formulation>
Ingredient Sourcing >
Manufacturing of product > 35% Profit Margin
Packaging>
Customer

Our Market Opportunity

The market value of the Asia Pacific has increased to more than US$70 billion
The Malaysian local cosmetics and toiletries market is valued at about MYR 3 billion, with an annual growth rate of 13%
The size of the Malaysian health supplement manufacturing industry is estimated to be MYR 914.59 million in 2018

Our Strategy

Indicative Usage of Funds

Production and manufacturing Facilities
Expanding the manufacturing facilities and buying new machinery
Inventory and Logistic
Stocking of raw ingredient purchase and product packaging
Research and Development
New Formulation testing and innovation in new product
Sales and Marketing
Engage B2B marketing across all channel to reach our target market

The Team

Dennis Tan

Managing Director

Cynthia Tong

Managing Director

Alan Ou

Management Executive

Term Sheet

Issuer: Crigen Accor Life Science Sdn Bhd, a private company limited by shares incorporated in Malaysia, a private limited company incorporated in Malaysia

Type of Equity: Ordinary Shares (“Shares”)

Fund Raising Period: 90 days

Pre Money Valuation: RM20,276,342

Minimum Fundraising Target: RM 500,000

Maximum Fundraising Target: RM 1,500,000

Price per Share: RM 2.03

Minimum Equity Offered: 2.40%

Maximum Equity Offered: 6.88%

Minimum Shares Offered: 246306

Maximum Shares Offered: 738917

Minimum Investment Amount: RM 5,014

Rewards

Impact on Shareholding Structure Upon Completion of the Offering

Investor Eligibility: Retail, Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.

Pre Emptive Rights

Type of Shares

Information

Closing Period: 14 working days after the end of the Fundraising Period.

Use of Proceeds: 20% for Sales & Marketing, 50% for Production & Manufacturing Facilities, 20% for Inventory & Logistics, 10% for Research & Development.

Subscription Procedure: An Investment Agreement for the subscription of the Shares (subject to review if required or necessary).

Disclaimer: The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by the Issuer, Crigen Accor Life Science Sdn Bhd to Ata Plus Sdn Bhd, either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following :
The financial information listed on the Deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalisation table, the term sheet, and management accounts.
The financial forecasts and projections have been prepared by the Issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness.
The Issuer agrees that; all information concerning the product, business and the assets of the Issuer that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respects and is not misleading or deceptive whether by inclusion or omission.
Should the Investor require more information, they can do so by contacting Crigen Accor Life Science Sdn Bhd directly at [email protected] or by clicking on the ‘CONTACT’ button available on the Deal Page.

Disclosure: This issuer is referred by a 3rd party which is . Ata Plus is not associated or related to the issuer and the referral party.

Disclaimer by Securities Commission

(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period

(ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007

(iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Issuer	Crigen Accor Life Science Sdn Bhd, a private company limited by shares incorporated in Malaysia
Type of Equity	Ordinary Shares (“Shares”)
Fund Raising Period	90 days
Pre Money Valuation	RM20,276,342
Minimum Fundraising Target	RM 500,000
Maximum Fundraising Target	RM 1,500,000
Price per Share	RM 2.03
Minimum Equity Offered	2.40%
Maximum Equity Offered	6.88%
Minimum Shares Offered	246306
Maximum Shares Offered	738917
Minimum Investment Amount	RM 5,014
Investor Eligibility	Retail, Angel, Sophisticated, and/or Institutional Investors, subject to the applicable investment limits prescribed under the Securities Commission’s Guidelines on Recognised Markets.
Closing Period	14 working days after the end of the Fundraising Period.
Use of Proceeds	20% for Sales & Marketing, 50% for Production & Manufacturing Facilities, 20% for Inventory & Logistics, 10% for Research & Development.
Subscription Procedure	An Investment Agreement for the subscription of the Shares (subject to review if required or necessary).
Disclaimer	The information, calculations and remarks expressed on this term sheet or on any other part of the platform are based on information provided, disclosed and presented by the Issuer, Crigen Accor Life Science Sdn Bhd to Ata Plus Sdn Bhd, either in part or in whole. Ata Plus disclaims responsibility for the accuracy, completeness and/or validity of these information, and hence will not be held liable for any inaccurate, inappropriate or incomplete information presented on this term sheet or on any other part of the platform subject to the following : The financial information listed on the Deal page is provided by the Issuer; which includes the financial forecasts and projections, the capitalisation table, the term sheet, and management accounts. The financial forecasts and projections have been prepared by the Issuer based on assumptions that have not been reviewed and certified by an independent certified accountant for its reasonableness. The Issuer agrees that; all information concerning the product, business and the assets of the Issuer that have been furnished to Ata Plus Sdn Bhd for the purpose of the equity crowdfunding campaign is true, complete, and accurate in all material respects and is not misleading or deceptive whether by inclusion or omission. Should the Investor require more information, they can do so by contacting Crigen Accor Life Science Sdn Bhd directly at [email protected] or by clicking on the ‘CONTACT’ button available on the Deal Page.
Disclaimer by Securities Commission	(i) No shares will be alotted or issued based on this document after six months from the closing of the offer period (ii) This issue, offer or invitation for the offering is a proposal not requiring authorisation of the Securities Commission under section 212(8) of the CMSA 2007 (iii) This document has not been reviewed by the Securities Commission Malaysia. The Securities Commission does not recommend nor assumes responsibility for any information including any statement, opinion or report disclosed in relation to this fund raising exercise and makes no representation as to its accuracy or completeness. The Securities Commission expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the information disclosed.

Risk Disclaimer

Investing in equity crowdfunding involves certain risks that include uncertainty of returns, lack of liquidity, dilution, material events and lack of control. Investments should be done as part of a diversiﬁed portfolio. ATA PLUS offers investment opportunities to investors who understands these risks in making their own investment decisions.

PLEASE READ THE FULL RISK WARNING BEFORE DECIDING TO INVEST.

This page is approved as a ﬁnancial promotion by ATA PLUS Sdn. Bhd., which is authorized and regulated by the Security Commission of Malaysia. Deals that are up for investment are only offered to members of ata-plus.com on the basis of information provided by the companies concerned. ATA PLUS takes no responsibility for this information or for any recommendations or opinions made by the companies. For further information on this, please read our Term of Use.

Crigen Accor Life Science

Introduction

What We Do

The Challenge

Our Solution

Why Are We Different

Our Revenue Model

Our Market Opportunity

Our Strategy

Indicative Usage of Funds

The Team

Dennis Tan

Managing Director

Cynthia Tong

Managing Director

Alan Ou

Management Executive

Term Sheet

Register your interest here!

Please enter your details below

Risk Disclaimer